Analysts Have Conflicting Sentiments on These Healthcare Companies: Lexicon Pharmaceuticals (LXRX) and MaxCyte (MXCT)
at www.tipranks.com (Mon, 24-Aug 10:50 AM)
Strategic Genentech Partnership and Strong Cost Controls Mark Key Shifts in MaxCyte’s Second Quarter 2026
Market Chameleon (Thu, 13-Aug 10:38 AM)
